You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海普瑞(09989.HK)附屬依諾肝素鈉注射液產品獲得玻利維亞國家藥理學委員會上市批准
阿思達克 06-07 16:36
海普瑞藥業(09989.HK)公布,旗下全資附屬深圳市天道醫藥,作為供應商生產的依諾肝素鈉注射液產品Novonox,已獲得玻利維亞國家藥理學委員會的上市批准。

Novonox(依諾肝素)適用於血栓栓塞性疾病(深靜脈血栓)患者的預防;髖關節或膝關節的外科矯形手術;還適用於髖關節置換術後住院期間或出院;後長期預防靜脈性血栓疾病;高風險腹部、婦科或泌尿手術;結直腸手術;深靜脈血栓形成(DVT)的醫學預防;中度風險以上深靜脈栓塞患者,因中重度急性心功能不全(NYHA III或IV型心衰)導致臥床不起的患者,顯示急性呼吸衰竭或併發不需要機械通氣支持的慢性呼吸功能不全,排除感染性休克的急性呼吸道感染需要短期預防深靜脈血栓。

Novonox同樣適用於伴或不伴肺栓塞的深靜脈血栓治療;不穩定心絞痛或無Q波改變的心肌梗死治療,可以聯合阿司匹林用藥;急性st段抬高型心肌梗死(STEMI)的治療,包括藥物治療以及隨後進行經皮冠;狀動脈介入治療(PCI)患者。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account